The transition from clinical trials to everyday medical practice often reveals significant gaps in treatment adherence, and this pattern emerges clearly with fezolinetant, the first novel non-hormonal menopause treatment approved in over a decade. For women unable to use hormone therapy due to breast cancer history or other contraindications, this neurokinin-3 receptor antagonist represented a promising alternative for managing debilitating hot flashes and night sweats.
Analysis of nearly 10,000 women prescribed fezolinetant through 156 million patient records revealed concerning persistence patterns. Only one in five patients continued treatment beyond the initial prescription, with just 20.5% receiving a second prescription within the critical 28-90 day window. Among the cohort, 13.3% were over 65 and notably, 20.5% had breast cancer diagnoses—precisely the population most likely to benefit from non-hormonal alternatives. Despite FDA requirements for liver function monitoring, only 42% of continuing patients received appropriate testing within three months.
These real-world persistence rates contrast sharply with the controlled environment successes that led to FDA approval. The medication targets hypothalamic thermoregulation through a novel pathway, offering mechanistic advantages over existing options like gabapentin or clonidine. However, the low continuation rates suggest either inadequate symptom relief, tolerability issues, or barriers like cost and monitoring requirements that weren't apparent in clinical trials. This represents a critical implementation gap where promising laboratory and trial results fail to translate into sustained therapeutic benefit for the women who need alternatives to hormone therapy most urgently.